FDA advisory committee backs Merck’s Keytruda for bladder cancer

The FDA’s Oncologic Drugs Advisory Committee voted 9-4 that the benefits outweigh the risks of Merck’s (NYSE:MRK) Keytruda (pembrolizumab) for the treatment of bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

https://seekingalpha.com/news/3526955-fda-advisory-committee-backs-mercks-keytruda-for-nmibc